Clinical evaluation of 5-ALA/SFC for cisplatin induced renal injury

Conditions

Unresectable gastric cancer

Miyake M, Tanaka N, Ohnishi K, Nakai Y, Anai S, Yamaki K, Asakawa I, Nishimura N, Fujii T, Isohashi F, Fujimoto K.

2024-11-012 citations

A prospective study of oral 5-aminolevulinic acid to prevent adverse events in patients with localized prostate cancer undergoing low-dose-rate brachytherapy: Protocol of the AMBER study.

Miyake M, Tanaka N, Asakawa I, Yamaki K, Inoue T, Suzuki S, Hori S, Nakai Y, Anai S, Torimoto K, Toritsuka M, Nakagawa H, Tsukamoto S, Fujii T, Ohbayashi C, Hasegawa M, Kasahara M, Fujimoto K.

2020-06-173 citations

10.1016/j.conctc.2020.100593

Interventions

5-aminolevulinic acid

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Unresectable gastric cancer case

Exclusion criteria

Exclusion criteria: Contraindication cases of S-1 or cisplatin administration

Design outcomes

Primary

Measure	Time frame
Safety of 5-ALA/SFC as the prevention of renal failure supplement	—

Secondary

Measure	Time frame
Renal failure depression effect	—

Countries

Japan

Contacts

Public ContactTomoki Yamatuji

kawasaki medical school general surgery

kosaka.r@med.kawasaki-m.ac.jp0862252111

Outcome results

None listed